Page 68 - Binder2

The story that was sold—of targeted therapy, of lasting
relief—falls apart in silence.

And over time, so does trust.

We cannot ask patients to invest in precision medicine
while offering them a vague explanation when it fails.

We cannot sell biologics as breakthroughs and then
normalize failure without clarity.

We owe patients the truth: that biologics are powerful—but
not always welcome.

And until we acknowledge that, every therapy will arrive
with more promise than the system can deliver. Each new
biologic will enter the market wrapped in optimism—
marketed as precise, lasting, and transformative—only to
risk faltering under the same unspoken flaw: immune
rejection that no one is prepared to talk about.

It’s a frightening narrative because it leads to a simple,
unavoidable truth:
Nobody will take a drug they don’t trust.

Not for long. Not if it stops working. Not if they feel
misled. Not if they weren’t told the risks.

And trust, once lost, isn’t siloed. It doesn’t fall apart drug
by drug. It collapses across brands, across companies,
across the entire therapeutic category. When one
biologic fails without explanation, it casts doubt on the
next. And the next. And the next. The failures of Merck,
Johnson and Johnson, and Eli Lilly are everyone’s
failures.

66